Biotechnology powerhouse AstraZeneca has inked a landmark licensing agreement with China’s CSPC Pharmaceutical Group Ltd., potentially worth $18.5 billion, aimed at developing and commercializing weight-loss and type 2 diabetes therapies globally, the companies announced Friday. The deal marks a significant move in Western pharmaceutical investment in China and highlights the growing global race for obesity AstraZeneca China Obesity Drug Deal worth $18.5B boosts global weight-loss and diabetes pipeline
AstraZeneca China Obesity Drug Deal Worth Up to $18.5B
